title: Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.
abstract: Viral load (VL) rebound timing and set point were analyzed in 235 participants undergoing analytic treatment interruption (ATI) in 6 AIDS Clinical Trials Group studies. There was no significant association between rebound timing and ATI VL set point for those who rebounded ≤12 weeks. VL set points were lower in participants with rebound >12 weeks (P < 0.001) and participants treated during early infection (P < 0.001). Pre-antiretroviral therapy VL correlated with set point, though 68% of participants had a set point lower than pre-antiretroviral therapy VL. These results illustrate complex relationships between post-ATI virologic outcomes and the potential presence of biological factors mediating rebound timing and set point.
authors.affiliation: *Brigham and Women's Hospital, Harvard Medical School, Boston, MA; †University of North Carolina, Chapel Hill, NC; ‡Harvard T. H. Chan School of Public Health, Boston, MA; §University of Pittsburgh, Pittsburgh, PA; ‖Ohio State University, Columbus, OH; and ¶Massachusetts General Hospital and Ragon Institute, Harvard Medical School, Boston, MA.
authors.forename: Graham C
authors.initials: GC
authors.lastname: Treasure
authors.forename: Evgenia
authors.initials: E
authors.lastname: Aga
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Bosch
authors.forename: John W
authors.initials: JW
authors.lastname: Mellors
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kuritzkes
authors.forename: Michael
authors.initials: M
authors.lastname: Para
authors.forename: Rajesh T
authors.initials: RT
authors.lastname: Gandhi
authors.forename: Jonathan Z
authors.initials: JZ
authors.lastname: Li
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D066264:Datasets as Topic; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D008297:Male; D012367:RNA, Viral / Q000032:analysis; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects*; D028761:Withholding Treatment
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral